Gilberto Fisone

List of Publications by Year
in descending order

120 papers	10,886 citations	31949 53 h-index	31818 101 g-index
123 all docs	123 docs citations	123 times ranked	9654 citing authors

#	Article	IF	Citations
1	Disrupted <i>Cacna1c</i> gene expression perturbs spontaneous Ca ²⁺ activity causing abnormal brain development and increased anxiety. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	15
2	NMDA Receptor and L-Type Calcium Channel Modulate Prion Formation. Cellular and Molecular Neurobiology, 2021, 41, 191-198.	1.7	3
3	A Guide to the Generation of a 6-Hydroxydopamine Mouse Model of Parkinsonâ€™s Disease for the Study of Non-Motor Symptoms. Biomedicines, 2021, 9, 598.	1.4	18
4	Involvement of Autophagy in Levodopaâ€Induced Dyskinesia. Movement Disorders, 2021, 36, 1137-1146.	2.2	8
5	On the Role of Adenosine A2A Receptor Gene Transcriptional Regulation in Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2019, 13, 683.	1.4	6
6	Atypical but not typical antipsychotic drugs ameliorate phencyclidine-induced emotional memory impairments in mice. European Neuropsychopharmacology, 2019, 29, 616-628.	0.3	8
7	Sleep Disorders in Rodent Models of Parkinsonâ€™s Disease. Frontiers in Pharmacology, 2019, 10, 1414.	1.6	29
8	Signal transduction in l-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression. Journal of Neural Transmission, 2018, 125, 1171-1186.	1.4	35
9	Midbrain circuits that set locomotor speed and gait selection. Nature, 2018, 553, 455-460.	13.7	313
10	An interactive framework for whole-brain maps at cellular resolution. Nature Neuroscience, 2018, 21, 139-149.	7.1	204
11	cJun N-terminal kinase (JNK) mediates cortico-striatal signaling in a model of Parkinson's disease. Neurobiology of Disease, 2018, 110, 37-46.	2.1	24
12	A neural network for intermale aggression to establish social hierarchy. Nature Neuroscience, 2018, 21, 834-842.	7.1	95
13	Inhibition of mTORC1 Signaling Reverts Cognitive and Affective Deficits in a Mouse Model of Parkinsonâ€™s Disease. Frontiers in Neurology, 2018, 9, 208.	1.1	44
14	Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson's disease model. Nature Biotechnology, 2017, 35, 444-452.	9.4	278
15	The histamine H3 receptor antagonist thioperamide rescues circadian rhythm and memory function in experimental parkinsonism. Translational Psychiatry, 2017, 7, e1088-e1088.	2.4	31
16	Dopamine Depletion Impairs Bilateral Sensory Processing in the Striatum in a Pathway-Dependent Manner. Neuron, 2017, 94, 855-865.e5.	3.8	75
17	The non-coding RNA BC1 regulates experience-dependent structural plasticity and learning. Nature Communications, 2017, 8, 293.	5.8	42
18	<scp>l</scp>â€DOPAâ€Induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?. European Journal of Neuroscience, 2017, 45, 73-91.	1.2	56

#	Article	IF	Citations
19	Somatosensory map expansion and altered processing of tactile inputs in a mouse model of fragile X syndrome. Neurobiology of Disease, 2016, 96, 201-215.	2.1	46
20	Differential regulation of the phosphorylation of Trimethyl-lysine27 histone H3 at serine 28 in distinct populations of striatal projection neurons. Neuropharmacology, 2016, 107, 89-99.	2.0	10
21	A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA â€“Induced Dyskinesia and â^†FosB Expression. Biological Psychiatry, 2016, 79, 362-371.	0.7	48
22	Involvement of the Striatal Medium Spiny Neurons of the Direct Pathway in the Motor Stimulant Effects of Phencyclidine. International Journal of Neuropsychopharmacology, 2015, 19, pyv134.	1.0	5
23	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Progress in Neurobiology, 2015, 132, 96-168.	2.8	379
24	Editorial (Thematic Issue: Understanding the Role of Heteroreceptor Complexes in the Central) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542	0.7	29
25	Dopamine Signaling Leads to Loss of Polycomb Repression and Aberrant Gene Activation in Experimental Parkinsonism. PLoS Genetics, 2014, 10, e1004574.	1.5	49
26	Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice. Experimental Neurology, 2014, 261, 733-743.	2.0	29
27	Phosphodiesterase 10A controls D1-mediated facilitation of GABA release from striato-nigral projections under normal and dopamine-depleted conditions. Neuropharmacology, 2014, 76, 127-136.	2.0	27
28	Cognitive Impairment and Dentate Gyrus Synaptic Dysfunction in Experimental Parkinsonism. Biological Psychiatry, 2014, 75, 701-710.	0.7	56
29	A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions. Frontiers in Behavioral Neuroscience, 2014, 8, 290.	1.0	110
30	Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32ÂkDa and inhibition of protein phosphatase-1. Neuropharmacology, 2013, 72, 197-203.	2.0	44
31	Group III and subtype 4 metabotropic glutamate receptor agonists: Discovery and pathophysiological applications in Parkinson's disease. Neuropharmacology, 2013, 66, 53-64.	2.0	66
32	Prion formation correlates with activation of translation-regulating protein 4E-BP and neuronal transcription factor Elk1. Neurobiology of Disease, 2013, 58, 116-122.	2.1	10
33	Operant behavior to obtain palatable food modifies ERK activity in the brain reward circuit. European Neuropsychopharmacology, 2013, 23, 240-252.	0.3	20
34	mGlu5R promotes glutamate AMPA receptor phosphorylation via activation of PKA/DARPP-32 signaling in striatopallidal medium spiny neurons. Neuropharmacology, 2013, 66, 179-186.	2.0	20
35	Operant behavior to obtain palatable food modifies neuronal plasticity in the brain reward circuit. European Neuropsychopharmacology, 2013, 23, 146-159.	0.3	41
36	Understanding cognitive deficits in Parkinsonâ€™s disease: lessons from preclinical animal models. Learning and Memory, 2013, 20, 592-600.	0.5	54

#	Article	IF	Citations
37	Dopamine-Dependent Long-Term Depression at Subthalamo-Nigral Synapses Is Lost in Experimental Parkinsonism. Journal of Neuroscience, 2013, 33, 14331-14341.	1.7	29
38	Dopamine- and cAMP-regulated Phosphoprotein of 32-kDa (DARPP-32)-dependent Activation of Extracellular Signal-regulated Kinase (ERK) and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in Experimental Parkinsonism. Journal of Biological Chemistry, 2012, 287, 27806-27812.	1.6	77
39	Neuronal signaling and behavior. Frontiers in Behavioral Neuroscience, 2012, 6, 72.	1.0	1
40	Molecular Mechanisms of l-DOPA-Induced Dyskinesia. International Review of Neurobiology, 2011, 98, 95-122.	0.9	47
41	Deciphering the Actions of Antiparkinsonian and Antipsychotic Drugs on cAMP/DARPP-32 Signaling. Frontiers in Neuroanatomy, 2011, 5, 38.	0.9	18
42	L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission. Frontiers in Behavioral Neuroscience, 2011, 5, 71.	1.0	147
43	Convulsant Doses of a Dopamine D1 Receptor Agonist Result in Erk-Dependent Increases in Zif268 and Arc/Arg3.1 Expression in Mouse Dentate Gyrus. PLoS ONE, 2011, 6, e19415.	1.1	63
44	Activation of Metabotropic Glutamate 4 Receptors Decreases L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease. Journal of Parkinson's Disease, 2011, 1, 339-346.	1.5	23
45	Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate l-DOPA-induced dyskinesia. Experimental Neurology, 2011, 232, 240-250.	2.0	39
46	Haloperidol Regulates the State of Phosphorylation of Ribosomal Protein S6 via Activation of PKA and Phosphorylation of DARPP-32. Neuropsychopharmacology, 2011, 36, 2561-2570.	2.8	65
47	Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia. Neurobiology of Disease, 2010, 38, 434-445.	2.1	92
48	Distinct Changes in cAMP and Extracellular Signal-Regulated Protein Kinase Signalling in L-DOPA-Induced Dyskinesia. PLoS ONE, 2010, 5, e12322.	1.1	111
49	Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14845-14850.	3.3	299
50	HDAC inhibitors conquer polycomb proteins. Cell Cycle, 2010, 9, 2713-2721.	1.3	29
51	mTORC1 signaling in Parkinson disease and L-DOPA-induced dyskinesia: A sensitized matter. Cell Cycle, 2010, 9, 2785-2790.	1.3	21
52	Monitoring dyskinesia with Zif. Experimental Neurology, 2010, 226, 11-14.	2.0	1
53	Histone H3 Phosphorylation is Under the Opposite Tonic Control of Dopamine D2 and Adenosine A2A Receptors in Striatopallidal Neurons. Neuropsychopharmacology, 2009, 34, 1710-1720.	2.8	85
54	Inhibition of mTOR Signaling in Parkinsonâ€™s Disease Prevents <scp>l</scp> -DOPAâ€“Induced Dyskinesia. Science Signaling, 2009, 2, ra36.	1.6	237

#	Article	IF	Citations
55	Opposing effects of ERK and p38â€JNK MAP kinase pathways on formation of prions in GT1â€1 cells. FASEB Journal, 2009, 23, 613-622.	0.2	30
56	<scp>l</scp>â€DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. Journal of Neurochemistry, 2009, 108, 621-633.	2.1	164
57	Looking BAC at striatal signaling: cell-specific analysis in new transgenic mice. Trends in Neurosciences, 2009, 32, 538-547.	4.2	196
58	3.3 Intracellular Dopamine Signaling. , 2009, , 100-117.		0
59	Parkinson's disease: Levodopaâ€induced dyskinesia and signal transduction. FEBS Journal, 2008, 275, 1392-1399.	2.2	95
60	The GTP-binding protein Rhes modulates dopamine signalling in striatal medium spiny neurons. Molecular and Cellular Neurosciences, 2008, 37, 335-345.	1.0	68
61	Lrrk2 and Î±-synuclein are co-regulated in rodent striatum. Molecular and Cellular Neurosciences, 2008, 39, 586-591.	1.0	36
62	Regulation of DARPP-32 phosphorylation by Î”9-tetrahydrocannabinol. Neuropharmacology, 2008, 54, 31-35.	2.0	35
63	Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology, 2008, 54, 815-823.	2.0	154
64	Dopamine D1 vs D5 receptor-dependent induction of seizures in relation to DARPP-32, ERK1/2 and GluR1-AMPA signalling. Neuropharmacology, 2008, 54, 1051-1061.	2.0	45
65	Delayed, context- and dopamine D1 receptor-dependent activation of ERK in morphine-sensitized mice. Neuropharmacology, 2008, 55, 230-237.	2.0	30
66	Expression of X-chromosome linked inhibitor of apoptosis protein in mature purkinje cells and in retinal bipolar cells in transgenic mice induces neurodegeneration. Neuroscience, 2008, 156, 515-526.	1.1	3
67	d-Aspartate Prevents Corticostriatal Long-Term Depression and Attenuates Schizophrenia-Like Symptoms Induced by Amphetamine and MK-801. Journal of Neuroscience, 2008, 28, 10404-10414.	1.7	106
68	Critical Involvement of cAMP/DARPP-32 and Extracellular Signal-Regulated Protein Kinase Signaling in L-DOPA-Induced Dyskinesia. Journal of Neuroscience, 2007, 27, 6995-7005.	1.7	400
69	Activation of the cAMP/PKA/DARPP-32 Signaling Pathway is Required for Morphine Psychomotor Stimulation but not for Morphine Reward. Neuropsychopharmacology, 2007, 32, 1995-2003.	2.8	43
70	Signaling in the basal ganglia: Postsynaptic and presynaptic mechanisms. Physiology and Behavior, 2007, 92, 8-14.	1.0	39
71	Psychoactive drugs and regulation of the cAMP/PKA/DARPP-32 cascade in striatal medium spiny neurons. Neuroscience and Biobehavioral Reviews, 2007, 31, 79-88.	2.9	55
72	Altered dopaminergic innervation and amphetamine response in adult Otx2 conditional mutant mice. Molecular and Cellular Neurosciences, 2006, 31, 293-302.	1.0	29

#	Article	IF	Citations
73	Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2receptors. Journal of Neurochemistry, 2006, 96, 482-488.	2.1	146
74	Increased D1dopamine receptor signaling in levodopa-induced dyskinesia. Annals of Neurology, 2005, 57, 17-26.	2.8	356
75	Cannabinoid Action Depends on Phosphorylation of Dopamine- and cAMP-Regulated Phosphoprotein of 32 kDa at the Protein Kinase A Site in Striatal Projection Neurons. Journal of Neuroscience, 2005, 25, 8432-8438.	1.7	117
76	Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism and Related Disorders, 2005, 11, S25-S29.	1.1	113
77	Regulation of striatal tyrosine hydroxylase phosphorylation by acute and chronic haloperidol. European Journal of Neuroscience, 2004, 20, 1108-1112.	1.2	45
78	Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum. Journal of Neurochemistry, 2004, 86, 451-459.	2.1	114
79	DARPP-32: An Integrator of Neurotransmission. Annual Review of Pharmacology and Toxicology, 2004, 44, 269-296.	4.2	639
80	DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia. Parkinsonism and Related Disorders, 2004, 10, 281-286.	1.1	48
81	The role of DARPP-32 in the actions of drugs of abuse. Neuropharmacology, 2004, 47, 14-23.	2.0	117
82	Plasma membrane and vesicular glutamate transporter mRNAs/proteins in hypothalamic neurons that regulate body weight. European Journal of Neuroscience, 2003, 18, 1265-1278.	1.2	116
83	Loss of bidirectional striatal synaptic plasticity in L-DOPAâ€"induced dyskinesia. Nature Neuroscience, 2003, 6, 501-506.	7.1	791
84	Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4305-4309.	3.3	172
85	Some Aspects on the Anatomy and Function of Central Cholecystokinin Systems. Basic and Clinical Pharmacology and Toxicology, 2002, 91, 382-386.	0.0	28
86	Regulation of Tyrosine Hydroxylase Activity and Phosphorylation at Ser19 and Ser40 via Activation of Glutamate NMDA Receptors in Rat Striatum. Journal of Neurochemistry, 2002, 74, 2470-2477.	2.1	55
87	Activation of extracellular signal-regulated kinases 1 and 2 by depolarization stimulates tyrosine hydroxylase phosphorylation and dopamine synthesis in rat brain. European Journal of Neuroscience, 2002, 15, 769-773.	1.2	80
88	Regulation of Na+, K+ -ATPase Isoforms in Rat Neostriatum by Dopamine and Protein Kinase C. Journal of Neurochemistry, 2002, 73, 1492-1501.	2.1	69
89	Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature, 2002, 418, 774-778.	13.7	174
90	Dopamine D1 Receptor-Induced Gene Transcription Is Modulated by DARPP-32. Journal of Neurochemistry, 2001, 75, 248-257.	2.1	39

#	Article	IF	Citations
91	Dopamine D2receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum. European Journal of Neuroscience, 2001, 13, 773-780.	1.2	105
92	Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 1856-1860.	3.3	190
93	Î¼- and Î´-opioid receptor agonists inhibit DARPP-32 phosphorylation in distinct populations of striatal projection neurons. European Journal of Neuroscience, 1999, 11, 2182-2186.	1.2	39
94	Requirement for DARPP-32 in mediating effect of dopamine D2 receptor activation. European Journal of Neuroscience, 1999, 11, 2589-2592.	1.2	25
95	Activation of dopamine D2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms. Neuroscience, 1999, 88, 1005-1008.	1.1	64
96	The DARPP-32/protein phosphatase-1 cascade: a model for signal integration1Published on the World Wide Web on 22 January 1998.1. Brain Research Reviews, 1998, 26, 274-284.	9.1	152
97	Activation of adenosine A2A and dopamine D1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience, 1998, 84, 223-228.	1.1	113
98	Na+,K+-ATPase Phosphorylation in the Choroid Plexus: Synergistic Regulation by Serotonin/Protein Kinase C and Isoproterenol/cAMP-PK/PP-1 Pathways. Molecular Medicine, 1998, 4, 258-265.	1.9	20
99	Effects of okadaic acid, calyculin A, and PDBu on state of phosphorylation of rat renal Na⁺-K⁺-ATPase. American Journal of Physiology - Renal Physiology, 1998, 275, F863-F869.	1.3	18
100	Na+,K+-ATPase in the Choroid Plexus. Journal of Biological Chemistry, 1995, 270, 2427-2430.	1.6	85
101	Phosphorylation of DARPPâ€32 Is Regulated by GABA in Rat Striatum and Substantia Nigra. Journal of Neurochemistry, 1994, 63, 1766-1771.	2.1	32
102	N-terminal galanin fragments inhibit the hippocampal release of acetylcholine in vivo. Brain Research, 1993, 612, 258-262.	1.1	30
103	Regulation by the neuropeptide cholecystokinin (CCK-8S) of protein phosphorylation in the neostriatum. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 11277-11281.	3.3	37
104	Galanin and galanin antagonists: molecular and biochemical perspectives. Trends in Pharmacological Sciences, 1992, 13, 312-317.	4.0	209
105	Mechanism of the galanin induced increase in acetylcholine release in vivo from striata of freely moving rats. Brain Research, 1992, 589, 33-38.	1.1	12
106	Galanin inhibits the potassium-evoked release of acetylcholine and the muscarinic receptor-mediated stimulation of phosphoinositide turnover in slices of monkey hippocampus. Brain Research, 1991, 568, 279-284.	1.1	61
107	Galanin Reduces Carbachol Stimulation of Phosphoinositide Turnover in Rat Ventral Hippocampus by Lowering Ca2+Influx Through Voltage-Sensitive Ca2+Channels. Journal of Neurochemistry, 1991, 56, 739-747.	2.1	99
108	Assay for Galanin Receptor. Methods in Neurosciences, 1991, , 225-234.	0.5	29

#	Article	IF	Citations
109	Chapter 30 Functional aspects of acetylcholine-galanin coexistence in the brain. Progress in Brain Research, 1990, 84, 279-287.	0.9	10
110	Activity of centrally administered galanin fragments on stimulation of feeding behavior and on galanin receptor binding in the rat hypothalamus. Journal of Neuroscience, 1990, 10, 3695-3700.	1.7	167
111	Galanin receptor and its ligands in the rat hippocampus. FEBS Journal, 1989, 181, 269-276.	0.2	103
112	N-terminal galanin-(1-16) fragment is an agonist at the hippocampal galanin receptor.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 9588-9591.	3.3	109
113	Chapter 7 Galanin in the cholinergic basal forebrain: histochemical, autoradiographic and in vivo studies. Progress in Brain Research, 1989, 79, 85-91.	0.9	10
114	Galanin inhibits the muscarinic stimulation of phosphoinositide turnover in rat ventral hippocampus. European Journal of Pharmacology, 1988, 148, 479-480.	1.7	81
115	Modulation of phospholipid methylation in rat striatum by the corticostriatal pathway. Brain Research, 1988, 461, 194-198.	1.1	2
116	Regulation of the Release of Coexisting Neurotransmitters. Annual Review of Pharmacology and Toxicology, 1988, 28, 285-310.	4.2	270
117	Galanin inhibits acetylcholine release in the ventral hippocampus of the rat: histochemical, autoradiographic, in vivo, and in vitro studies.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 7339-7343.	3.3	310
118	Role of the hippocampus in the sex-dependent regulation of eating behavior: Studies with kainic acid. Physiology and Behavior, 1986, 38, 321-326.	1.0	34
119	Qualitative differences in the effects of adenosine analogs on the cholinergic systems of rat striatum and hippocampus. Naunyn-Schmiedeberg's Archives of Pharmacology, 1986, 334, 86-91.	1.4	5
120	Mediation by the corticostriatal input of the in vivo increase in rat striatal acetylcholine content induced by 2-chloroadenosine. Biochemical Pharmacology, 1983, 32, 2993-2996.	2.0	3